• (S)-(+)-Dimethindene maleate Protocol Guide

  2026-08-22

  This practical guide helps researchers use (S)-(+)-Dimethindene maleate as a dossier-defined M2 muscarinic receptor antagonist while accounting for its additional histamine H1 receptor antagonism. It is intended for controlled pharmacological experiments, not diagnostic, therapeutic, or medical use, and prepared solutions should be used promptly rather than stored long term.

• C34 TLR4 Inhibitor: A Mechanistic Assay Guide

  2026-08-21

  C34 is a selective TLR4 inhibitor for dissecting inflammatory signaling in macrophages, enterocytes, and microglia. This guide connects product pharmacology with a recent Taxus chinensis study to improve assay design, controls, and interpretation.

• PBS Liposomes for Macrophage Study Controls

  2026-08-20

  PBS Liposomes provide a non-cytotoxic, phagocytosis-matched control for separating liposome uptake from clodronate-driven macrophage depletion. This guide explains paired in vivo designs, assay workflows, storage decisions, and troubleshooting strategies, while using the TRPM3 structural literature as a model for mechanistically disciplined controls.

• Trolox for Redox-Controlled Pancreatic Organoids

  2026-08-20

  Trolox provides a practical antioxidant benchmark for separating oxidative injury from intrinsic pancreatic organoid growth effects. This guide connects the compound’s assay-standard role with reproducible pancreatic ductal organoid workflows, including dosing, controls, readouts, and troubleshooting.

• BAPTA-AM (B4758): Protocol and QC Guide

  2026-08-19

  BAPTA-AM (SKU B4758) is a cell-permeable calcium chelator for experimentally lowering intracellular free Ca²⁺ and testing calcium-dependent responses. It is suited to controlled cellular and biochemical workflows, but results should be interpreted with vehicle, calcium, magnesium, viability, and potassium-channel controls rather than as direct evidence of therapeutic efficacy.

• Leucomycin: From Biosynthesis to Assay Design

  2026-08-19

  Leucomycin and kitasamycin offer a powerful bridge between macrolide pharmacology and Streptomyces biosynthesis. This article presents an evidence-driven framework for connecting precursor flux, translational inhibition, resistance profiling, and assay interpretation.

• Anlotinib Hydrochloride: Mechanism & Research Use

  2026-08-18

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that suppresses VEGFR2, PDGFRβ, and FGFR1 signaling in angiogenesis models. Its nanomolar pathway activity, oral pharmacokinetic profile, and case-report evidence support cancer research applications, while clinical translation remains context-dependent.

• Angiotensin 1/2 (2-7): Assay Design Guide

  2026-08-18

  Explore how the Angiotensin 1/2 (2-7) peptide can be used to design fragment-resolved studies of renin-angiotensin signaling, blood pressure biology, and spike–receptor binding. This guide emphasizes assay controls, sample handling, and the experimental implications of recent peptide-binding evidence.

• MK-1775: From Checkpoint Biology to Translation

  2026-08-17

  A translational framework for using MK-1775, a selective Wee1 kinase inhibitor, to connect G2 checkpoint biology with rigorous in vitro response measurement, combination strategy, and preclinical decision-making.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-17

  Masitinib (AB1010), SKU A2942, provides dossier-defined inhibition of KIT, PDGFRα, and PDGFRβ for targeted kinase and mast-cell workflows. It is best suited to DMSO-based research and should not be selected for aqueous or ethanol-based protocols, broad-spectrum kinase screens, or experiments requiring paper-specific validation that is not available here.

• Cy7 NHS ester: Practical Labeling Guide

  2026-08-16

  Cy7 NHS ester (SKU A8109) is a sulfonated, water-soluble protein labeling dye for attaching near-infrared fluorescence to accessible amino groups in proteins and peptides. It is suited to aqueous biomolecule conjugation and near-infrared fluorescent imaging, but not to targets without suitable amino groups or long-term storage of prepared dye solutions.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-08-15

  The 1992 reference study showed that imidazoline α2-adrenergic receptor antagonists increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than simply by blocking α2-adrenoceptors. Its combination of islet perifusion, 86Rb efflux, and whole-cell patch-clamp experiments provides a mechanistic framework for interpreting Tolazoline in islet function research.

• Viral RIPK3 Degradation Controls Inflammation

  2026-08-14

  Liu and colleagues identified a viral inducer of RIPK3 degradation, or vIRD, that couples the orthopoxvirus SCF ubiquitin machinery to proteasomal removal of a central necroptosis kinase. Their genetic and infection studies show that vIRD is not simply an immune-evasion factor: by suppressing RIPK3–MLKL signaling, it reshapes viral replication, inflammation, and disease severity in a virus- and host-dependent manner.

• How Kinase Inhibitors Promote p38α Dephosphorylation

  2026-08-14

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by stabilizing a phosphatase-compatible activation-loop conformation. This structural and kinetic framework suggests a route to designing inhibitors that suppress signaling through coordinated control of kinase activity and kinase deactivation.

• Nebivolol Hydrochloride: Reading Negative Data

  2026-08-13

  Nebivolol hydrochloride is a potent β1-adrenoceptor antagonist for receptor-focused cardiovascular studies. This article explains how a drug-sensitized yeast mTOR assay can sharpen target interpretation without converting a negative TOR result into an unsupported claim.

15312 records 1/1021 page Next 12345 下5页 Last page